# SKYSCRAPER-05 (NCT04832854)

> A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04832854
- Phase: PHASE2
- Status: TERMINATED
- Sponsor: Hoffmann-La Roche
- Conditions: Non-Small Cell Lung Cancer (NSCLC)
- Interventions: Atezolizumab; Tiragolumab; Carboplatin; Cisplatin; Pemetrexed; Gemcitabine; Paclitaxel
- Enrollment: 50
- Primary outcome: Number of Participants With Surgical Delays
- Primary outcome: Number of Participants With Operative and Post-operative Complications
- Primary outcome: Number of Participants With Surgical Cancellations Related to Study Treatment
- Primary outcome: Number of Participants With Adverse Events (AEs)
- Primary outcome: Major Pathological Response (MPR) Rate

## Indexed commentary on SKYSCRAPER-05 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 6
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=skyscraper-05-nct04832854